Natus Medical (NASDAQ:NTUS) Lowered to “Sell” at ValuEngine

ValuEngine downgraded shares of Natus Medical (NASDAQ:NTUS) from a hold rating to a sell rating in a research note released on Thursday, ValuEngine reports.

Separately, Zacks Investment Research lowered shares of Natus Medical from a hold rating to a sell rating in a research report on Wednesday.

NTUS stock traded down $0.39 during midday trading on Thursday, hitting $31.18. 159,228 shares of the stock traded hands, compared to its average volume of 142,816. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -115.48 and a beta of 0.74. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.39 and a current ratio of 1.89. The company’s fifty day moving average is $32.72. Natus Medical has a 1-year low of $22.25 and a 1-year high of $34.89.

Natus Medical (NASDAQ:NTUS) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.46 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.01). The firm had revenue of $131.76 million for the quarter, compared to analyst estimates of $130.00 million. Natus Medical had a negative net margin of 1.79% and a positive return on equity of 10.54%. The firm’s quarterly revenue was down 6.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.43 EPS. Sell-side analysts anticipate that Natus Medical will post 1.5 EPS for the current year.

In other news, CEO Jonathan Kennedy sold 6,684 shares of Natus Medical stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $31.54, for a total value of $210,813.36. Following the sale, the chief executive officer now owns 148,441 shares in the company, valued at $4,681,829.14. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.65% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in NTUS. Cramer Rosenthal Mcglynn LLC acquired a new stake in shares of Natus Medical in the fourth quarter valued at about $45,658,000. State Street Corp acquired a new stake in shares of Natus Medical in the fourth quarter valued at about $39,079,000. Victory Capital Management Inc. acquired a new stake in shares of Natus Medical in the fourth quarter valued at about $33,687,000. Bank of New York Mellon Corp acquired a new stake in shares of Natus Medical in the fourth quarter valued at about $22,851,000. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Natus Medical in the fourth quarter valued at about $14,814,000. Institutional investors and hedge funds own 90.68% of the company’s stock.

About Natus Medical

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.